Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
107 participants
OBSERVATIONAL
2017-11-15
2020-11-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Coffee on Hepatic Steatosis Induced by a High Fructose Diet
NCT00827450
French Cohort for the Study of Non-invasive Tests of Liver Lesions in NAFLD/NASH (FreSH Cohort)
NCT03695796
Study Visceral Adipose Tissue and Liver Stifness in a Retrospective Cohort of Diabetes Mellitus Patients
NCT04493814
Coffee Effect in HCV-related Hepatitis
NCT01572103
Identification of Biomarkers Related to Liver Fibrosis as New Therapeutic Targets
NCT03979417
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Or Metabolic syndrome defined by the IDF 2005 criteria:
* waist size\> 94cm (men) or\> 80cm (women)
* and the presence of at least two of the following criteria:
* blood pressure: Systolic ≥ 130mmHg OR diastolic ≥ 85 mmHg OR antihypertensive treatment
* Triglycerides ≥ 1.5g / L or lipid-lowering therapy
* HDL cholesterol \<0.4 g / L (men) or \<0.5 g / L (women) or lipid-lowering therapy
* fasting blood glucose:\> 1 g / L or type 2 diabetes AND Hepatic steatosis diagnosed on liver imaging And liver fibrosis (diagnosed with a FibroScan\> 6 KPa)
Exclusion Criteria
* Viral hepatitis and other chronic liver diseases
* Alcohol consumption\> 20g / day for women, 30g / day for men
* Liver biopsy or FibroScan dating more than 6 months before inclusion.
* History of bariatric surgery
* Serious psychiatric pathology (psychosis, dementia, severe depression) and patients under legal protection (tutelage, guardianship)
* Solid cancer or progressive hematology or \<2 years (except basal cell carcinoma or localized squamous cell carcinoma)
* Severe and terminal chronic renal insufficiency (estimated GFR \<30mL / min)
* Recent myocardial infarction \<6 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Versailles Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Hugues Blondon
Head of Hepatogastroenterology Service
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hugues BLONDON, Department head
Role: PRINCIPAL_INVESTIGATOR
Versailles Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier de Béziers
Béziers, , France
Centre hospitalier Métropole Savoie
Chambéry, , France
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, , France
Groupe Hospitalier Public Sud Oise
Creil, , France
Centre Hospitalier Intercommunal de Créteil
Créteil, , France
Centre Hospitalier de Gonesse
Gonesse, , France
Centre Hospitalier de Hyères
Hyères, , France
Centre Hospitalier Départemental Vendée
La Roche-sur-Yon, , France
Centre Hospitalier de Bretagne Sud
Lorient, , France
Hôpital de Melun
Melun, , France
Centre hospitalier Annecy Genevois
Metz-Tessy, , France
Centre hospitalier Montelimar
Montélimar, , France
Hôpital de Diaconesses
Paris, , France
Centre Hospitalier de Perpignan
Perpignan, , France
Centre Hospitalier de Saint Denis
Saint-Denis, , France
Centre Hospitalier de Sens
Sens, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-A01872-49
Identifier Type: REGISTRY
Identifier Source: secondary_id
P16/17_COCANASH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.